Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetirizine 0.24% in allergic conjunctivitis (CAC model)
NCT01551056Phase 3Completed
- Sponsor
- Aciex Therapeutics
- Start
- Mar 2012
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cetirizine in allergic conjunctivitis (AC), sponsored by Aciex Therapeutics. Started Mar 2012; status: completed.
02
Drugs
cetirizine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT01551056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01551056.